[Federal Register Volume 61, Number 237 (Monday, December 9, 1996)]
[Notices]
[Pages 64912-64913]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-31246]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 96M-0462]
Matritech, Inc.; Premarket Approval of the Matritech NMP22TM
Test Kit
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing its
approval of the application by Matritech, Inc., Newton, MA, for
premarket approval, under the Federal Food, Drug, and Cosmetic Act (the
act), of the Matritech NMP22TM Test Kit. After reviewing the
recommendation of the Immunology Devices Panel, FDA's Center for
Devices and Radiological Health (CDRH) notified the applicant, by
letter of July 2, 1996, of the approval of the application.
DATES: Petitions for administrative review by January 8, 1997.
ADDRESSES: Written requests for copies of the summary of safety and
effectiveness data and petitions for administrative review to the
Dockets Management Branch (HFA-305), Food and Drug Administration,
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: Peter E. Maxim, Center for Devices and
Radiological Health (HFZ-440), Food
[[Page 64913]]
and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850,
301-594-1293.
SUPPLEMENTARY INFORMATION: On November 7, 1994, Matritech, Inc.,
Newton, MA 02160, submitted to CDRH an application for premarket
approval of the Matritech NMP22TM Test Kit. The Matritech
NMP22TM Test Kit is an enzyme immunoassay for the in vitro
quantitative determination of nuclear matrix protein NMP22 in
stabilized voided urine. The Matritech NMP22TM Test Kit is
indicated as an aid in the management of patients with transition cell
carcinoma of the urinary tract (TCC/UT), after surgical treatment to
identify those patients with occult or rapidly recurring TCC/UT. The
Matritech NMP22TM Urine Collection Kit is intended for the
collection, stabilization, and transport of human urine which will be
tested using the Matritech NMP22TM Test Kit.
On November 30, 1995, the Immunology Devices Panel of the Medical
Devices Advisory Committee, an FDA advisory committee, reviewed and
recommended approval of the application. On July 2, 1996, CDRH approved
the application by a letter to the applicant from the Director of the
Office of Device Evaluation, CDRH.
A summary of the safety and effectiveness data on which CDRH based
its approval is on file in the Dockets Management Branch (address
above) and is available from that office upon written request. Requests
should be identified with the name of the device and the docket number
found in brackets in the heading of this document.
Opportunity for Administrative Review
Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any
interested person to petition, under section 515(g) of the act, for
administrative review of CDRH's decision to approve this application. A
petitioner may request either a formal hearing under 21 CFR part 12 of
FDA's administrative practices and procedures regulations or a review
of the application and CDRH's action by an independent advisory
committee of experts. A petition is to be in the form of a petition for
reconsideration under 21 CFR 10.33(b). A petitioner shall identify the
form of review requested (hearing or independent advisory committee)
and shall submit with the petition supporting data and information
showing that there is a genuine and substantial issue of material fact
for resolution through administrative review. After reviewing the
petition, FDA will decide whether to grant or deny the petition and
will publish a notice of its decision in the Federal Register. If FDA
grants the petition, the notice will state the issue to be reviewed,
the form of the review to be used, the persons who may participate in
the review, the time and place where the review will occur, and other
details.
Petitioners may, at any time on or before January 8, 1997, file
with the Dockets Management Branch (address above) two copies of each
petition and supporting data and information, identified with the name
of the device and the docket number found in brackets in the heading of
this document. Received petitions may be seen in the office above
between 9 a.m. and 4 p.m., Monday through Friday.
This notice is issued under the Federal Food, Drug, and Cosmetic
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10)
and redelegated to the Director, Center for Devices and Radiological
Health (21 CFR 5.53).
Dated: November 7, 1996.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and
Radiological Health.
[FR Doc. 96-31246 Filed 12-6-96; 8:45 am]
BILLING CODE 4160-01-F